Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
3.93% $13.23
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 467.85 mill |
EPS: | -0.750 |
P/E: | -17.64 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 35.36 mill |
Avg Daily Volume: | 0.446 mill |
RATING 2024-03-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -17.64 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.37x |
Company: PE -17.64 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 12.57 - 13.81 ( +/- 4.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Opaleye Management Inc. | Buy | 50 000 | Common Stock, par value $0.001 per share |
2024-03-22 | Baum Mark L | Buy | 9 000 | Common stock |
2024-03-20 | Opaleye Management Inc. | Buy | 50 600 | Common Stock, par value $0.001 per share |
2024-03-01 | Saharek John P. | Buy | 5 000 | Common stock |
2024-03-01 | Saharek John P. | Sell | 5 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
12.44 |
Last 96 transactions |
Buy: 5 373 190 | Sell: 3 289 598 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $13.23 (3.93% ) |
Volume | 0.830 mill |
Avg. Vol. | 0.446 mill |
% of Avg. Vol | 186.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $10.28 | N/A | Active |
---|
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.